Melanoma Clinical Trials

Showing 1261-1280 of 1,477 trials

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

NCT01131234

This phase I clinical trial is studying the side effects and best dose of giving gamma-secretase inhibitor RO4929097 and cediranib maleate together in treating patients with advanced solid tumors. Gamma-secretase inhibitor RO4929097 and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate also may stop the growth of tumor cells by blocking blood flow to the tumor.

Adult Anaplastic AstrocytomaAdult Anaplastic EpendymomaAdult Anaplastic Oligodendroglioma+49 more

National Cancer Institute (NCI)20 participantsStarted May 2010

Hamilton, Ontario, Canada • Toronto, Ontario, Canada

WITHDRAWN

Autonomic Phenotype Before and After Akt Inhibition

NCT01593579

Some Akt inhibitors have produced functional cardiovascular effects such as marked hypotension that may limit their clinical benefit. There are no current data on whether this autonomic failure presents in humans at clinically used doses. We will test the hypothesis that Akt inhibition causes an acute decrease in sympathetic tone and lowers blood pressure.

Diagnosis of Melanoma

Vanderbilt UniversityStarted May 2012

Nashville, Tennessee, United States

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Autonomic Phenotype Before and After Akt Inhibition

Related Searches

Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Pilot Study of Infrared Imaging of Cutaneous Melanoma

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma

NAM-Trial: Multiferon in Malignant Melanoma

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

Partner Assistance in Learning and Performing Skin Self-Examination

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy

Melanoma Simulation Model With Smartphone Devices: Training Physicians for Early Detection of Melanoma

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

Transient Infrared Imaging for Early Detection of Skin Cancer